Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Nov 30, 2025 | (FY)Aug 31, 2025 | (Q4)Aug 31, 2025 | (Q3)May 31, 2025 | (Q2)Feb 28, 2025 | (Q1)Nov 30, 2024 | (FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | -5.56%68K | -13.25%72K | ||||||||
| Gross profit | 5.56%-68K | 13.25%-72K | ||||||||
| Operating expense | 13.35%2.22M | -1.87%4.78M | 75.72%1.22M | -37.12%1.11M | -42.28%497K | 26.21%1.96M | -15.88%4.87M | -46.11%692K | 29.39%1.77M | -24.27%861K |
| Selling and administrative expenses | 13.35%2.22M | -1.87%4.78M | 75.72%1.22M | -37.12%1.11M | -42.28%497K | 26.21%1.96M | -15.88%4.87M | -46.11%692K | 29.39%1.77M | -24.27%861K |
| -General and administrative expense | 13.35%2.22M | -1.87%4.78M | 75.72%1.22M | -37.12%1.11M | -42.28%497K | 26.21%1.96M | -15.88%4.87M | -46.11%692K | 29.39%1.77M | -24.27%861K |
| Operating profit | -13.35%-2.22M | 1.92%-4.85M | -68.06%-1.28M | 37.12%-1.11M | 42.28%-497K | -26.21%-1.96M | 15.85%-4.94M | 44.11%-764K | -29.39%-1.77M | 24.27%-861K |
| Net non-operating interest income (expenses) | -25.69%107K | |||||||||
| Non-operating interest income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -25.69%107K | ---- |
| Other net income (expenses) | 212.50%375K | -10.33%330K | -18.54%167K | -134.68%-43K | 79.17%86K | 1,433.33%120K | 44.88%368K | -21.15%205K | 1,133.33%124K | 119.59%48K |
| Gain on sale of security | 129.00%229K | 2,275.00%95K | 182.05%32K | -611.76%-87K | 554.55%50K | 170.27%100K | -98.37%4K | 11.36%-39K | 241.67%17K | -122.00%-11K |
| Special income (charges) | ---- | --0 | ---- | ---- | ---- | ---- | --160K | ---- | ---- | ---- |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---160K | ---- | ---- | ---- |
| Other non-operating income (expenses) | 226.67%196K | -36.93%275K | 62.65%135K | -58.88%44K | -67.57%36K | -55.56%60K | -25.34%436K | --83K | --107K | --111K |
| Income before tax | -0.33%-1.84M | 1.25%-4.52M | -99.82%-1.12M | 29.77%-1.16M | 49.45%-411K | -17.78%-1.84M | 18.59%-4.58M | 64.44%-559K | -33.17%-1.65M | 32.19%-813K |
| Income tax | -41.94%18K | -26.19%31K | ||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -0.33%-1.84M | 1.52%-4.54M | -92.37%-1.14M | 29.77%-1.16M | 49.45%-411K | -17.78%-1.84M | 18.65%-4.61M | 63.44%-590K | -33.17%-1.65M | 32.19%-813K |
| Net income continuous operations | -0.33%-1.84M | 1.52%-4.54M | -92.37%-1.14M | 29.77%-1.16M | 49.45%-411K | -17.78%-1.84M | 18.65%-4.61M | 63.44%-590K | -33.17%-1.65M | 32.19%-813K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -0.33%-1.84M | 1.52%-4.54M | -92.37%-1.14M | 29.77%-1.16M | 49.45%-411K | -17.78%-1.84M | 18.65%-4.61M | 63.44%-590K | -33.17%-1.65M | 32.19%-813K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -0.33%-1.84M | 1.52%-4.54M | -92.37%-1.14M | 29.77%-1.16M | 49.45%-411K | -17.78%-1.84M | 18.65%-4.61M | 63.44%-590K | -33.17%-1.65M | 32.19%-813K |
| Diluted earnings per share | 0.00%-0.02 | 20.00%-0.04 | 0.00%-0.01 | 50.00%-0.01 | 0 | 0.00%-0.02 | 16.67%-0.05 | 50.00%-0.01 | -100.00%-0.02 | 0.00%-0.01 |
| Basic earnings per share | 0.00%-0.02 | 20.00%-0.04 | 0.00%-0.01 | 50.00%-0.01 | 0 | 0.00%-0.02 | 16.67%-0.05 | 50.00%-0.01 | -100.00%-0.02 | 0.00%-0.01 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.